At a Glance
- Company: Leica Biosystems and StatLab Medical Products
- Location: Danaher’s diagnostics business
- Deal value: Not disclosed, estimated ~$1 billion
- Focus area: Anatomical pathology instruments, consumables and workflow products
- Next steps: The transaction is expected to close by the end of 2026
What happened?
Leica Biosystems, part of Danaher, has agreed to acquire StatLab Medical Products in a move that expands its diagnostics and anatomical pathology footprint. The deal brings together Leica’s instruments and digital pathology capabilities with StatLab’s consumables and workflow products.
Why does it matter?
The acquisition strengthens Leica’s position in pathology labs by adding more of the tools and consumables used across the full workflow. It also reflects a broader industry trend toward recurring revenue, where consumables and lifecycle management are becoming increasingly important to margins.
Who’s behind it?
Leica Biosystems is a Danaher operating company focused on cancer diagnostics and pathology. StatLab Medical Products develops and manufactures histology, cytology and immunohistochemistry products for pathology laboratories.
How was it achieved?
Leica is buying StatLab from its private-equity owners, giving it access to a broader mix of instruments, reagents and consumables. The transaction also appears designed to support standardisation in pathology workflows, which can matter for both routine lab work and AI-enabled diagnostics.
What’s next?
Financial terms were not disclosed, though one analyst estimate suggested the value could exceed $1 billion. The deal is expected to close by the end of 2026, subject to customary approvals.